# A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

> **NCT03311308** · PHASE1 · RECRUITING · sponsor: **Yana Najjar** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03311308
- **Lead sponsor:** Yana Najjar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-07
- **Primary completion:** 2028-01
- **Final completion:** 2029-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311308, "A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03311308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*